Facilitated By

San Antonio Medical Foundation

A Randomized, Controlled, Open-Label, Global Phase 3 Study Comparing The Efficacy Of The ANTI-PD-1 Antibody BGB-A317 Versus Chemotherapy As Second Line Treatment In Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma.

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
GENEVA
Research Start Date
Status
Active

The primary objective of this study is to compare the overall survival (OS) following treatment with BGB-A317 vs. investigator chosen chemotherapy (ICC) when given as second line treatment in patients with advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

Collaborative Project
Clinical Care
Cancer
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.